BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Sanford-Burnham Medical Research Institute Collaborates With Pfizer Inc. (PFE) to Identify Targets for Treatment of Insulin Resistance and Diabetes


8/13/2013 6:57:47 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Sanford-Burnham Collaborates With Pfizer to Identify Targets for Treatment of Insulin Resistance and Diabetes

ORLANDO, FL --(Marketwired - August 13, 2013) - Sanford-Burnham Medical Research Institute (Sanford-Burnham) announced that it has entered into a collaboration with Pfizer Inc. to identify new therapeutic targets for preventing and treating complications of obesity and diabetes. The team will utilize novel screening tools including systems-biology approaches and technologies developed at Sanford-Burnham with the aim of discovering new therapeutic strategies for reducing insulin resistance in obesity and diabetes.

Under the three-year agreement, multi-disciplinary teams from Sanford-Burnham and Pfizer will collaborate to identify and validate new targets for drug discovery. The collaboration combines Sanford-Burnham's expertise in fundamental disease biology and muscle metabolism with Pfizer's expertise in drug discovery. Investigators will utilize Sanford-Burnham's Conrad Prebys Center for Chemical Genomics (Prebys Center) to screen for new relevant targets using investigational compounds from Pfizer as well as evaluate compounds previously identified from the NIH chemical library. Once the screening identifies compounds of interest, Sanford-Burnham and Pfizer scientists will collaborate to characterize and further study the "hit" compounds to understand their mechanism of action. These compounds will then be used as "probes" to identify novel therapeutic targets for the treatment of diabetes.

"Diabetes presents an enormous public health burden. There is an acute need to translate innovative science into potential new medicines for people living with this debilitating disease," said Tim Rolph, Vice President and Head of Cardiovascular and Metabolic Diseases Research Unit at Pfizer. "Pfizer's collaboration with Sanford-Burnham to use their cutting-edge screen designs is an example of our strategy to work with academic innovators to discover novel therapeutics for prevention and treatment of diabetes."

Pfizer will have access to Sanford-Burnham's team of world-class scientists and translational infrastructure dedicated to finding new approaches to targeting disease. Collaborating with researchers at a major pharmaceutical company will help Sanford-Burnham achieve its mission of translating high-impact science into new therapies. "This important collaboration focuses our tremendous scientific and translational firepower on a major medical problem -- complications of obesity-related diabetes. Working with Pfizer, we can more quickly bridge the gap between basic and translational research," said Stephen Gardell, Ph.D., senior director of scientific resources at Sanford-Burnham Medical Research Institute at Lake Nona.

The Prebys Center houses Sanford-Burnham's state-of-the-art screening facility established to accelerate the rate of commercialization of basic research in an independent medical research setting. Sanford-Burnham's drug discovery capabilities include: ultra-high throughput screening, high-content screening, phenotypic screening, and target deconvolution technologies. The Prebys Center is led and staffed by industry-trained professionals who work closely with Sanford-Burnham investigators and industry collaborators to translate scientific findings into actionable drug discovery projects.

About Insulin Resistance in Diabetes

It is well known that abnormalities of lipid metabolism in muscle are associated with insulin resistance in obese individuals where excess fat is deposited in many organs and tissues in the body including skeletal muscle. As fat accumulates, muscle - the major sugar-disposal site in the body - becomes insulin resistant and sugar is not cleared as effectively from the blood.

About Sanford-Burnham Medical Research Institute

Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham takes a collaborative approach to medical research with major programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is recognized for its National Cancer Institute-designated Cancer Center and expertise in drug discovery technologies. Sanford-Burnham is a nonprofit, independent institute that employs 1,200 scientists and staff in San Diego (La Jolla), California, and Orlando (Lake Nona), Florida. For more information, visit us at www.sanfordburnham.org.

Contact:

Deborah Robison

(407) 615-0072

drobison@sanfordburnham.org

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES